The present work examined the potential of utilizing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in each p53 wild-type (WT) breast tumor cells As well as in cells lacking functional p53 both by itself or in combination with tamoxifen, when the https://manleyj655vgq7.develop-blog.com/profile